Tag Archive for: FDA
![Coronavirus feat](https://canceradvocacy.org/wp-content/uploads/2020/03/Coronavirus-feat.jpg)
Coronavirus and Cancer Resources for Survivors
Cancer survivors have expressed concerns and questions about COVID-19, the coronavirus, and how they may be at higher risk due to their cancer history. Here are some resources about COVID-19 generally, and its impact for cancer survivors specifically. NCCS is seeking answers from public health experts on the coronavirus and its impact on cancer patients and survivors. Please leave a comment [...]
![Access to Unapproved Therapies](https://canceradvocacy.org/wp-content/uploads/childhood-cancer.jpg)
Exploring Access to Unapproved Therapies
In a series entitled, “When Unapproved Drugs Are the Only Hope,” Meg Tirrell of CNBC takes an in-depth look into the complicated…
![Balancing Patient Protections and Innovation](https://canceradvocacy.org/wp-content/uploads/FDA-Logo-495x400.jpg)
Balancing Patient Protections and Innovation: NCCS Applauds FDA Action to Regulate Laboratory-Developed Tests
The National Coalition for Cancer Survivorship (NCCS) commends the Food and Drug Administration (FDA) for taking critical steps to…
![Balancing Patient Protections and Innovation](https://canceradvocacy.org/wp-content/uploads/FDA-Logo-495x400.jpg)
NCCS Joins Alliance for Childhood Cancer in Submitting Comments to FDA
NCCS joined the Alliance for Childhood Cancer in submitting comments to the Food and Drug Administration (FDA) following the January…
![Dome Thumbnail starburst](https://canceradvocacy.org/wp-content/uploads/2012/12/Dome_Thumbnail_starburst.png)
NCCS Joins Colleagues in Offering Advice Regarding Standards for Sharing Patient-Specific Clinical Trials Data
The National Coalition for Cancer Survivorship joined colleagues in the cancer advocacy community in offering advice to the Food and…
![Dome Thumbnail starburst](https://canceradvocacy.org/wp-content/uploads/2012/12/Dome_Thumbnail_starburst.png)
NCCS Submits Comments in Follow-Up to FDA Patient-Focused Public Meeting
NCCS submitted comments to the Food and Drug Administration (FDA) as a follow-up to the Lung Cancer Patient-Focused Drug Development…
![Dome Thumbnail starburst](https://canceradvocacy.org/wp-content/uploads/2012/12/Dome_Thumbnail_starburst.png)
NCCS Joins Patient Advocate Colleagues in Commenting on FDA Document on Expedited Programs for Serious Conditions
NCCS joined its patient advocate colleagues in the Cancer Leadership Council in comments on a Food and Drug Administration (FDA) document…
![NCCS Starburst Thumbnail](https://canceradvocacy.org/wp-content/uploads/2012/12/NCCS_Starburst_Thumbnail.jpg)
Shelley Fuld Nasso of NCCS Is Panelist at FDA Lung Cancer Meeting
Shelley Fuld Nasso, NCCS Senior Director of Policy, was a panelist at the June 28, 2013, Food and Drug Administration (FDA) meeting…
![Dome Thumbnail starburst](https://canceradvocacy.org/wp-content/uploads/2012/12/Dome_Thumbnail_starburst.png)
NCCS and Colleagues Comment on FDA Strategies Regarding Drug Shortages
NCCS joined colleagues in the cancer patient and provider community in providing advice to the Food and Drug Administration (FDA) regarding…
![Dome Thumbnail starburst](https://canceradvocacy.org/wp-content/uploads/2012/12/Dome_Thumbnail_starburst.png)
NCCS Joins Colleagues in Offering Comments on an Alternative Approval Pathway
NCCS joined its colleagues in the patient advocate and cancer care provider community in offering comments to the Food and Drug Administration…
![Dome Thumbnail starburst](https://canceradvocacy.org/wp-content/uploads/2012/12/Dome_Thumbnail_starburst.png)
“Making Cancer Drugs Less Expensive” Linking Clinical Value to Price
In an opinion piece in the Washington Post, Hagop Kantarjian, Leonard Zwelling, and Tito Fojo offer a perspective on cancer drug prices…